|Table 1: Selection of potential markers/targets and pathways implicated in the development of radioresistant prostate cancer, their significance in predicting radiation therapy (RT) failure, and potential therapeutic inventions/agents.|
|OLN+: occult lymph node metastasis; AR: androgen receptor; PKA: protein kinase A; EGFR: epithelial growth factor receptor; VEGF-R: vascular endothelial growth factor receptor; PI3K/AKT/mTOR: phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian target of rapamycin; NF-κB/Stat3: transcription factors nuclear factor-kappa B (NF-κB) and signal transducers and activators of transcription 3 (Stat3), COX-2: cyclooxygenase 2; CGA: chromogranin A;|
‡: significant prediction of RT failure has been reported.
±: significant prediction of RT failure has not been reported.
NYD: not yet determined.